The common clinical strategy for therapy of acute relapses in MS is either by high dose, short-term pulse therapy with glucocorticoid4 or by immunomodulatory treatments such as interferon beta (IFN-β)5, glatiramer acetate6, and mitoxantrone7. This evidence concerns the gene IFNB1 and myeloid sarcoma.